ReviewEuropean radiology2024
Ten years of gadolinium retention and deposition: ESMRMB-GREC looks backward and forward.
Review in European radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Rationales for Non-standard GBCA Dosing-Low?-High?-When? and Why?: A Literature-based Study.Investigative radiology · 2026Pooled it
- ESR Essentials: gadolinium-wise MRI-practice recommendations by the European Society for Magnetic Resonance in Medicine and Biology.European radiology · 2025Guideline
- Manganese-derived biomaterials for tumor diagnosis and therapy.Journal of nanobiotechnology · 2024Pooled it
- Pediatric magnetic resonance urography from patient preparation to post-processing: basics and controversies.Pediatric radiology · 2026Review
- Use of gadolinium-based contrast agents in head and neck cancer diagnosis, staging, and monitoring: current applications and future perspectives.European radiology · 2026Review
- Gadolinium-based contrast agents in pediatric MRI: renal safety, risk mitigation, and emerging alternatives.Pediatric radiology · 2026Review
- Brain Tumor Imaging with Iopamidol CEST MRI: In Vivo Detection and Validation.Chemical & biomedical imaging · 2026Article
- Repeated gadolinium-based contrast agent exposure increases depression-like behavior in rats.Japanese journal of radiology · 2026Article
- Managing healthcare for female BRCA carriers in the population screening era: developing a harmonized national policy for surveillance and risk-reduction.Israel journal of health policy research · 2026Article
- MRI of atypical lipomatous tumor: does contrast help? A multicenter study.Skeletal radiology · 2025Article
- Symptoms Associated With Gadolinium Exposure: Different Patterns and Rates Between Linear and Macrocyclic Gadolinium-Based Contrast Agents.Investigative radiology · 2025Article
- Mitigating Head Position Bias in Perivascular Fluid Imaging: LD-ALPS, a Novel Method for DTI-ALPS Calculation.NeuroSci · 2025Article
- Gadolinium toxicity: mechanisms, clinical manifestations, and nanoparticle role.Archives of toxicology · 2025Review
- Hypersensitivity Reactions to Gadolinium-Based Contrast Agents: Update From an Allergist's Point of View.Clinical and translational allergy · 2025Review
- MRA evaluation of aneurysms treated with woven endobridge (WEB) devices or coils: an inter- and intra-observer reliability study.Neuroradiology · 2025Article
- From routine to selective: how updated MRI guidelines reshape gadolinium use in Germany.Neurological research and practice · 2025Article
- Pharmacokinetics of metal excretion following different doses of sodium EDTA infusion.Metallomics : integrated biometal science · 2025Article
- CT surveillance for type 1 autoimmune pancreatitis: cumulative radiation dose and diagnostic performance for disease relapse.European radiology · 2025Article
- Enhanced detection of glioblastoma vasculature with superparamagnetic iron oxide nanoparticles and MRI.Scientific reports · 2025Article
- Applications and Efficacy of Iron Oxide Nanoparticles in the Treatment of Brain Tumors.Pharmaceutics · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2014, for the first time, visible hyperintensities on unenhanced T1-weighted images in the nucleus dentatus and globus pallidus of the brain were associated with previous Gadolinium-based contrast agent (GBCA) injections and gadolinium deposition in patients with normal renal function. This led to a frenzy of retrospective studies with varying methodologies that the European Society of Magnetic Resonance in Medicine and Biology Gadolinium Research and Educational Committee (ESMRMB-GREC) summarised in 2019. Now, after 10 years, the members of the ESMRMB-GREC look backward and forward and review the current state of knowledge of gadolinium retention and deposition. CLINICAL RELEVANCE STATEMENT: Gadolinium deposition is associated with the use of linear GBCA but no clinical symptoms have been associated with gadolinium deposition. KEY POINTS : • Traces of Gadolinium-based contrast agent-derived gadolinium can be retained in multiple organs for a prolonged time. • Gadolinium deposition is associated with the use of linear Gadolinium-based contrast agents. • No clinical symptoms have been associated with gadolinium deposition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.